Ionis Pharmaceuticals, Inc. (IONS)
43.54
-0.46
(-1.05%)
USD |
NASDAQ |
Oct 02, 16:00
43.60
+0.06
(+0.14%)
After-Hours: 20:00
Ionis Pharmaceuticals Enterprise Value : 7.346B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 7.346B |
| October 01, 2026 | 7.422B |
| September 30, 2026 | 7.530B |
| September 29, 2026 | 7.736B |
| September 28, 2026 | 7.683B |
| September 25, 2026 | 7.505B |
| September 24, 2026 | 7.391B |
| September 23, 2026 | 7.411B |
| September 22, 2026 | 7.712B |
| September 21, 2026 | 7.572B |
| September 18, 2026 | 7.495B |
| September 17, 2026 | 7.878B |
| September 16, 2026 | 7.562B |
| September 15, 2026 | 7.961B |
| September 14, 2026 | 8.655B |
| September 11, 2026 | 9.114B |
| September 10, 2026 | 9.352B |
| September 09, 2026 | 9.413B |
| September 08, 2026 | 9.528B |
| September 04, 2026 | 9.756B |
| September 03, 2026 | 9.763B |
| September 02, 2026 | 10.29B |
| September 01, 2026 | 10.05B |
| August 31, 2026 | 10.13B |
| August 28, 2026 | 10.25B |
| Date | Value |
|---|---|
| August 27, 2026 | 10.48B |
| August 26, 2026 | 10.63B |
| August 25, 2026 | 10.66B |
| August 24, 2026 | 10.41B |
| August 21, 2026 | 10.03B |
| August 20, 2026 | 9.867B |
| August 19, 2026 | 10.21B |
| August 18, 2026 | 10.01B |
| August 17, 2026 | 9.846B |
| August 14, 2026 | 9.615B |
| August 13, 2026 | 9.389B |
| August 12, 2026 | 9.498B |
| August 11, 2026 | 9.314B |
| August 10, 2026 | 9.566B |
| August 07, 2026 | 9.503B |
| August 06, 2026 | 9.160B |
| August 05, 2026 | 9.110B |
| August 04, 2026 | 9.256B |
| August 03, 2026 | 9.160B |
| July 31, 2026 | 8.709B |
| July 30, 2026 | 8.960B |
| July 29, 2026 | 9.085B |
| July 28, 2026 | 9.294B |
| July 27, 2026 | 9.403B |
| July 24, 2026 | 9.501B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Biogen, Inc. | 39.55B |
| BridgeBio Pharma, Inc. | 15.82B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
| Pfizer Inc. | 210.23B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -114.65M |
| Revenue (Quarterly) | 267.95M |
| Total Expenses (Quarterly) | 382.60M |
| EPS Diluted (Quarterly) | -0.6931 |
| Gross Profit Margin (Quarterly) | 96.13% |
| Profit Margin (Quarterly) | -42.79% |
| Earnings Yield | -7.98% |
| Normalized Earnings Yield | -8.406 |